Dov Bergwerk, Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 12, 2026, reporting the acquisition of 9,433 restricted share units on November 10, 2026.

Key Highlights

  • Grant date: Bergwerk received 9,433 restricted share units (RSUs) on November 10, 2026.
  • Price: The RSUs were acquired at a price of $0, according to the filing.
  • Vesting schedule: 2,358 RSUs vest on each of November 10, 2027, November 10, 2028, and November 10, 2029, with 2,359 RSUs vesting on November 10, 2030.
  • Underlying security: Each RSU represents a contingent right to receive one ordinary share, or at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • Beneficial ownership following transaction: Bergwerk directly holds 9,433 derivative securities following the reported transaction.
  • Role: Bergwerk is identified in the filing as Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd.

RSU Grant Details for Teva's Interim Chief Legal Officer Bergwerk

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 12, 2026, Dov Bergwerk, serving as Interim Chief Legal Officer at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), was granted 9,433 restricted share units on November 10, 2026. The filing records the transaction under Table II, covering derivative securities, with a transaction code of "A" indicating an acquisition.

The filing states that each RSU "represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share." The grant was made at a price of $0, and Bergwerk's direct beneficial ownership of derivative securities following the transaction totals 9,433 RSUs.

The vesting schedule disclosed in the filing spreads over four years: 2,358 RSUs vest on each of November 10, 2027, November 10, 2028, and November 10, 2029, with the remaining 2,359 RSUs vesting on November 10, 2030. The filing was signed by Dov Bergwerk on November 12, 2026, and no Table I non-derivative transactions were reported.

What Was Disclosed

Dov Bergwerk, Interim Chief Legal Officer at Teva Pharmaceutical Industries Ltd., reported the acquisition of 9,433 RSUs on November 10, 2026, with a four-year vesting schedule, at a grant price of $0, resulting in direct beneficial ownership of 9,433 derivative securities.